Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603655 | 0.90 | ATM (0.45) | MTNR1AMTNR1BNQO2TRPV1NPY5R | |
| SCHEMBL605986 | 0.83 | TRPV1 (0.42) | TRPV1SLC6A9 | |
| SCHEMBL14489162 | 0.81 | NPY5R (0.45) | MTNR1AMTNR1BNQO2NPY5R | |
| SCHEMBL15617046 | 0.79 | TRPV1 (0.54) | MTNR1AMTNR1BNQO2TRPV1NPY5R | |
| SCHEMBL15544456 | 0.79 | TRPV1 (0.54) | MTNR1AMTNR1BNQO2TRPV1NPY5R | |
| SCHEMBL15617246 | 0.79 | TRPV1 (0.54) | MTNR1AMTNR1BNQO2TRPV1NPY5R | |
| SCHEMBL605742 | 0.78 | HTR2A (0.45) | MTNR1AMTNR1BNQO2NPY5RSLC6A9 | |
| SCHEMBL603483 | 0.78 | ATM (0.43) | SLC6A9 | |
| SCHEMBL4271807 | 0.77 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL601872 | 0.76 | ATM (0.46) | TRPV1SLC6A9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-8846743-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2603481-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | MTNR1A 687/4885MTNR1B 780/4885NQO2 1072/4885 |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | MTNR1A 687/4885MTNR1B 780/4885NQO2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.